Preoperative Endocrine Therapy for Older Women with Breast Cancer: Renewed Interest in an Old Idea

Ellis, Matthew J.

doi:10.1177/107327480000700607

Cited by 22 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may have led to an underestimation of tumor responses. A review of the literature suggests that the initial response rates to preoperative endocrine therapy exceed 50-60% for patients with receptor-positive disease [12]. 79 of 134 cases (59%) in the chemo-/radiotherapy and 29/64 cases (45%) in the chemotherapy group received preoperative endocrine treatment which implies that the difference in complete remission rates in both groups cannot be attributed to the additional endocrine therapy.…”

Section: Discussionmentioning

confidence: 99%

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

et al. 2003

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Such long-term therapy was used in those old, frail, and infirm patients who could not tolerate surgery. Since that time, the concept of using a medical treatment before surgery has developed.…”

mentioning

confidence: 99%

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

Cataliotti

Buzdar

Noguchi

et al. 2006

Cancer

316

191

View full text Add to dashboard Cite

Although oxytocin (OT) and oxytocin receptor (OTR) are known for roles in parturition and milk let‐down, they are not hypothalamus‐restricted. OT is important in nurturing and opposition to stress. Transcripts encoding OT and OTR have been reported in adult human gut, and OT affects intestinal motility. We tested the hypotheses that OT is endogenous to the enteric nervous system (ENS) and that OTR signaling may participate in enteric neurophysiology. Reverse transcriptase polymerase chain reaction confirmed OT and OTR transcripts in adult mouse and rat gut and in precursors of enteric neurons immunoselected from fetal rats. Enteric OT and OTR expression continued through adulthood but was developmentally regulated, peaking at postnatal day 7. Coincidence of the immunoreactivities of OTR and the neural marker Hu was 100% in the P3 and 71% in the adult myenteric plexus, when submucosal neurons were also OTR‐immunoreactive. Co‐localization with NeuN established that intrinsic primary afferent neurons are OTR‐expressing. Because OTR transcripts and protein were detected in the nodose ganglia, OT signaling might also affect extrinsic primary afferent neurons. Although OT immunoreactivity was found only in ∼1% of myenteric neurons, extensive OT‐immunoreactive varicosities surrounded many others. Villus enterocytes were OTR‐immunoreactive through postnatal day 17; however, by postnatal day 19, immunoreactivity waned to become restricted to crypts and concentrated at crypt‐villus junctions. Immunoelectron microscopy revealed plasmalemmal OTR at enterocyte adherens junctions. We suggest that OT and OTR signaling might be important in ENS development and function and might play roles in visceral sensory perception and neural modulation of epithelial biology. J. Comp. Neurol. 512:256–270, 2009. © 2008 Wiley‐Liss, Inc.

show abstract

“…In these cases, TAM is therefore administered as a secondline therapy. There is also increasing amounts of data supporting the use of aromatase inhibitors in the preoperative setting, which may lead to increased opportunities for breast-conserving local therapy, as well as suitable treatment alternatives for those who are not candidates for surgery or chemotherapy (Dixon, 2004;Dixon and Miller, 2003;Ellis, 2000).…”

Section: Antiestrogens Versus Aromatase Inhibitors As Endocrine Theramentioning

confidence: 99%

X-Box Binding Protein-1 in Breast Cancer

Clarke¹

2005

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE (DD-MM-YYYY) 01-08-2005 REPORT TYPE PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERGeorgetown University Washington, DC 20007 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTThe factors driving resistance to antiestrogens are unknown. Comparing the transcriptomes of antiestrogen responsive and resistant MCF-7 variants by serial analysis of gene expression, we have implicated several genes, including the human X-box binding protein-1 (XBP-1). XBP-1 is a cAMP response element (CRE) binding protein associated with estrogen receptor (ER) expression in gene expression profiles of human breast cancers. We hypothesize that overexpression of XBP-1 and/or activation of CRE contribute functionally to the ability of responsive cells to survive the metabolic stresses induced by exposure to antiestrogens. We also hypothesize that measuring expression of the XBP-1 protein will assist in better identifying antiestrogen resistant and/or responsive tumors. Aim 1: We will further study the likely functional role of XBP-1/CRE by overexpression through transfection into responsive cells, and inhibiting expression in resistant cells using novel CRE oligonucleotide decoys, antisense and/or ribozymes. Effects of these molecular manipulations on responsiveness to antiestrogens will be studied in vitro and in vivo. Aim 2: We will explore the prognostic and predictive significance of XBP-1 expression in a unique series of human breast cancer biopsies. Thus, we will assess the extent to which XBP-1 is an independent prognostic factor, and whether it is associated with response to antiestrogens. Where possible, we will explore whether XBP-1 expression data allow us to build better predictive/prognostic models. SUBJECT TERMS INTRODUCTIONAntiestrogens are effective in premenopausal and postmenopausal patients, and in the ...

show abstract

Preoperative Endocrine Therapy for Older Women with Breast Cancer: Renewed Interest in an Old Idea

Cited by 22 publications

References 37 publications

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

X-Box Binding Protein-1 in Breast Cancer

Contact Info

Product

Resources

About